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Asthma is the most common chronic disease in young children. About 40% of all preschool children regularly
wheeze during common cold infections. The heterogeneity of wheezing phenotypes early in life and various
anatomical and emotional factors unique to young children present significant challenges in the clinical
management of this problem. Anti-inflammatory therapy, mainly consisting of inhaled corticosteroids (ICS), is the
cornerstone of asthma management. Since Leukotrienes (LTs) are chemical mediators of airway inflammation in
asthma, the leukotriene receptor antagonists (LTRAs) are traditionally used as potent anti-inflammatory drugs in the
long-term treatment of asthma in adults, adolescents, and school-age children. In particular, montelukast decreases
airway inflammation, and has also a bronchoprotective effect. The main guidelines on asthma management have
confirmed the clinical utility of LTRAs in children older than five years. In the present review we describe the most
recent advances on the use of LTRAs in the treatment of preschool wheezing disorders. LTRAs are effective in
young children with virus-induced wheeze and with multiple-trigger disease. Conflicting data do not allow to reach
definitive conclusions on LTRAs efficacy in bronchiolitis or post-bronchiolitis wheeze, and in acute asthma. The
excellent safety profile of montelukast and the possibility of oral administration, that entails better compliance from
young children, represent the main strengths of its use in preschool children. Montelukast is a valid alternative to
ICS especially in poorly compliant preschool children, or in subjects who show adverse effects related to long-term
steroid therapy.
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Asthma is the most common chronic disease of the air-
ways in young children [1]. About 40% of all preschool
children regularly wheeze during common cold infections.
Although about two-thirds of these children lose their
symptoms after the age of six years, the disease places a
considerable burden on the child, the child’s family, and
society because of the high prevalence and lack of good
treatment control [2]. Moreover, the heterogeneity of
wheezing phenotypes early in life presents significant chal-
lenges in the clinical management of this problem.
Anti-inflammatory therapy is the cornerstone of
asthma management. Studies of the efficacy of inhaled
corticosteroids (ICS) in preschool children have given
conflicting results. Some studies show that ICS are effect-
ive in improving symptoms and lung function [3-8],* Correspondence: santamar@unina.it
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reproduction in any medium, provided the oralthough safety data are worrisome [9], while others find
no effect at all on the prevention of progression to estab-
lished asthma [10-12]. The most plausible explanation
for these differences is that there is no single wheezing
phenotype in young children, since the disease may be
provoked by respiratory viruses, allergens, exercise and
exposure to smoke or other pollutants [13]. In addition
to this, there are various anatomical, physiological and
emotional factors unique to young children, especially
infants, that result in significant difficulties and chal-
lenges to inhalation therapy [14]. All these troubles can
be easily overcome by oral drug administration.
The leukotriene receptor antagonists (LTRAs) are
traditionally used as anti-inflammatory drugs in the
long-term treatment of asthma in adults, adolescents,
and school-age children [15-17]. This review sum-
marizes the most recent development on the use of
LTRAs in the treatment of preschool wheezing
disorders.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Montella et al. Italian Journal of Pediatrics 2012, 38:29 Page 2 of 9
http://www.ijponline.net/content/38/1/29Leukotrienes mechanism of action and biological
effects
Leukotrienes (LTs) are chemical mediators of airway in-
flammation in asthma, produced from membrane phos-
pholipids via the 5-lipoxygenasepathwayof the arachidonic
acid cascade (Figure 1) [18]. After activation by mechan-
ical, chemical, or physical stimuli, cytosolic phospholip-
ase A2 translocates to the membrane to liberate
membrane-bound arachidonic acid. Free arachidonic
acid either can be converted by the cyclooxygenase path-
way to form prostanoids (prostaglandins, prostacyclin
and thromboxane) or, alternatively, can follow the 5-
lipoxygenase pathway to form LTs. In combination with
the 5-lipoxygenase activating protein, the 5-lipoxygenase
enzyme acts on arachidonic acid to form the 5-
hydroperoxyeicosatetraenoic acid, which is then con-
verted to the nonpeptide leukotriene LTA4. LTA4 can
then be converted to the cysteinyl leukotrienes (CysLTs)
LTC4, LTD4 and LTE4 which provoke bronchial and vas-
cular constriction and therefore play a central role in the
pathophysiology of asthma [18].
The CysLTs are synthesized by several cells, including
neutrophils, eosinophils, mast cells, alveolar macro-
phages, epithelial cells and vascular endothelial cells,
which are present or recruited to the lung when airways
inflammation occurs. The production of LTs by these
cells depends on the selective expression of the enzymes
involved in the metabolic pathway. LTA4 may be directly
released into the extracellular environment and there be
metabolized by other cells (transcellular biosynthesis).
This pathway results in LTB4 production by bronchial
epithelial cells, despite 5-lipoxygenase enzyme is absent
[18].Figure 1 Leukotriene biosynthesis. LT, leukotriene; 5-LO,
5-lipoxygenase; FLAP, five lipoxygenase activating protein; 5-HPETE,
5- hydroperoxyeicosatetraenoic acid; Cys-LTs, cysteinyl leukotrienes.Due to its activity in cellular recruitment and activa-
tion, LTB4 is an important proinflammatory mediator,
also involved in the stimulation of the interleukin bio-
synthesis by T lymphocytes and monocytes, with conse-
quent increase in vascular permeability and mucous
production [19]. Conversely, CysLTs act on the smooth
muscle cells, inducing a constrictive effect much stron-
ger than that determined by methacoline or histamine.
Furthermore, they are potent in eliciting bronchocon-
striction, mucous production and vasodilatation, and
may enhance the airways hyperresponsiveness that is
characteristic of the asthmatic disease [20].
CysLTs receptor antagonists bind the LTD4 receptor
and prevent the interaction between the receptor and its
physiological ligands [21]. Due to this receptor obstruc-
tion, LTs cannot activate the signal transduction that
leads to bronchoconstriction. Among LTRAs, zafirlukast,
pranlukast and montelukast have been approved in sev-
eral countries for asthma treatment of adults and chil-
dren. Montelukast (MK-0476), is the most specific and
powerful LTs receptor antagonist, and is the only LTRA
that has been approved for preschool children use in
several countries including Italy. In addition to its use as
controller drug in allergic and viral-induced asthma, it
decreases also bronchial hyperreactivity and prevents
bronchial obstruction induced by physical activity at pre-
school and school age [22,23].
CysLTs production is greatly increased in allergen- or
exercise-induced asthma, particularly during exacerba-
tions [24]. Children with steroid-naïve mild persistent,
severe persistent and unstable asthma have high levels of
exhaled CysLTs [25]. Moreover, CysLTs and LTB4 are
significantly increased also in children with mild and
moderate to persistent asthma treated with low or high
doses of inhaled ICS [26].
CysLTs activate type 1 and type 2 leukotriene receptors
(CysLT1 and CysLT2) on cell membranes [27]. CysLT1
receptors are localized primarily on pulmonary smooth
muscle cells. Activation of these receptors by CysLT
leads to decreased activity of respiratory cilia, increased
mucous secretion, increased venopermeability and pro-
motion of eosinophils into the airways [28]. This, in
turn, induces airway smooth-muscle proliferation and
may play a role in the development of airway remodel-
ing. Moreover, CysLTs are the most potent bronchocon-
strictive agents discovered, being 100–1000 times more
potent than histamines [29].
Scientific evidences about LTRAs in preschool
children
Monotherapy with montelukast
Only few short- or long-term randomized controlled
trials (RCTs) with LTRAs have been conducted in pre-
school age.
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A study of asthmatic children aged 2–5 years demon-
strated that administration of 5 mg/die of montelukast
for two days protects against cold air-induced bronchial
hyperreactivity [30]. This finding was later confirmed
in patients who showed a significant decrease in
methacoline-induced bronchial reactivity after a four-
weeks treatment with montelukast [22].
In atopic children with asthma, monotherapy with
montelukast for 28 days was reported to be effective for
reducing airway resistance and bronchial inflammation
[31], and for improving lung function and symptoms
score [32]. Finally, an Australian RCT conducted in chil-
dren with mild intermittent asthma, demonstrated that a
short course of montelukast, introduced at the first signs
of an asthma episode, resulted in a significant reduction
in acute health care resource utilization, symptoms, time
off from school, and parental time off from work [33].
However, no significant effect on hospitalization rate,
duration of symptoms, use of bronchodilators and sys-
temic steroids was found, and finally, the number of
symptom-free days, one of the primary outcomes of
therapeutic efficacy, was not considered by the authors.
Long-term monotherapy
In 2001, a large multicenter, double-blind, international
study on 689 preschool children with multi-trigger
wheezing and persistent symptoms showed that daily
montelukast given over three months is associated with
more symptom-free days (34% versus 28% in the placebo
group) [34]. In another study, Davies and coworkers
found that patients aged 2 to 5 years with mild to mod-
erate persistent asthma receiving long-term therapy with
montelukast had similar rates of asthma-related health
care resource utilization compared with those receiving
usual care with cromolyn or ICS [35]. In 2005 the PREVIA
study (PREvention of Viral Induced Asthma) showed
that a 1-year course of montelukast in children with
virus-induced asthma significantly reduces asthma
exacerbations and the use of rescue medications [36].
Despite several criticisms, particularly regarding the
number of symptom-free days that was not significantly
different in the two groups (76% versus 73% in the pla-
cebo group, p = 0.059), and the use of systemic steroids
that was not significantly reduced after treatment [37],
the PREVIA study remains one of the few RCTs in pre-
school children with mild intermittent asthma that
proves that prolonged treatment with montelukast
reduces the consumption of ICS at a high rate (39.8%).
Studies that compared either short- or long-term
treatment with LTRAs given as monotherapy to other
antiasthma controller drugs in preschool children
showed that montelukast is as effective as ICS. Szefler
and coworkers evaluated the efficacy of montelukastversus budesonide in 349 children, mostly at preschool
age, with mild persistent asthma, and found no differ-
ences between the two groups as far as drug tolerabil-
ity, time to first additional anti-asthma medications and
time to first severe exacerbation over a 52 weeks-study
period [38]. Another small RCT assessed the efficacy of
montelukast or fluticasone given as monotherapy versus
placebo for three months [39]. Both drugs decreased
asthma-like symptoms and improved the daily symp-
toms score, even though fluticasone appeared more ef-
fective than placebo. Nevertheless, the symptoms score
also improved in the placebo group, suggesting that
asthma-like symptoms, that are commonly associated
with respiratory virus infections in preschool age, may
spontaneously improve. Unfortunately, this study was
conducted on a limited population and therefore the
statistical power might be questioned [39].
In addition, the results of a RCT of preschool children,
most of whom had positive asthma predictive indices,
showed that the episodic use of either budesonide or
montelukast for 7 days during an asthma exacerbation
does not increase the proportion of symptom-free days
or decrease oral corticosteroids and health care
resources use [40]. Nevertheless, both drugs appeared ef-
fective in decreasing the severity of symptoms, particu-
larly in cases with positive asthma predictive indices or
with more severe clinical manifestations.
Finally, a retrospective analysis of 2034 asthmatic chil-
dren treated with montelukast and fluticasone as mono-
therapy, showed that both drugs decrease rescue
medications use and hospital visits [41]. In particular, in
children aged 2 to 5 years, montelukast was associated
to less emergency visits compared to subjects aged 6 to
14 years. This finding was taken by authors to conclude
that the beneficial effects of LTRAs may be mainly
observed in preschool children.
All the above findings indicate that LTRAs may be
beneficial in preschool wheeze. However, since only two
RCTs compared montelukast to ICS [39,40], more com-
parative studies of preschool children treated with
LTRAs versus ICS should hopefully be promoted
[42,43]. Likewise, the intermittent use of montelukast
has been evaluated only in mild, or moderate-to severe
intermittent wheeze [33,40], and this modality of treat-
ment might be extended to children with severe recur-
rent or persistent symptoms.
Combined therapy (montelukast plus inhaled steroids)
Combined therapy with montelukast and ICS in pre-
school children has been poorly investigated. One study
of 194 children (22% aged 2 to 5 years) showed that
montelukast added to the usual treatment with ICS
reduced the risk of worsening asthma symptoms and un-
scheduled physician visits during the annual September
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found that montelukast more effectively reduces acute
asthma episodes if started before the viral season, when
the exacerbation rate is higher [36]. Very few evidences
support the effectiveness of montelukast combined to
ICS as long-term asthma treatment or during an acute
exacerbation [42,45].
Montelukast and bronchiolitis
CysLTs are increased in respiratory secretions from
infants with acute viral bronchiolitis and their levels re-
main significantly high at short-term follow-up, suggest-
ing a possible role of CysLTs in the pathogenesis of the
disease [46]. However, the results of the published RCTs
are controversial. Amirav and coworkers demonstrated
that montelukast given to infants with a first episode of
bronchiolitis from the hospital admission until discharge
did not reduce the length of stay, or the cytokine levels
in nasal lavage fluid, nor improved the clinical severity
scores [47]. Likewise, no significant benefit of montelu-
kast administered both at 4 and 20 weeks after the onset
of respiratory symptoms was shown in a large study of
infants with post respiratory syncytial virus (RSV) bron-
chiolitis [48]. A small RCT confirmed this result, show-
ing that montelukast given for three months after
hospital admission for RSV bronchiolitis did not reduce
the respiratory symptoms during both the treatment and
the follow up periods [49]. All these findings appear con-
flicting with the conclusions of one of the first studies of
RSV bronchiolitis that showed that montelukast results
in significant improvement of symptoms score and in
decrease of nighttime symptoms and daytime cough
[50]. Finally, a recent RCT demonstrated that montelu-
kast given for 3 months reduces eosinophilic degranula-
tion (p < 0.01) and decreases the number of recurrent
wheezing episodes (p = 0.039) in children 6 to 24 months-
old with post-RSV bronchiolitis [51].
These conflicting results do not allow to reach defini-
tive conclusions, and highlight the need for further stud-
ies on children with recurrent wheeze associated with
RSV bronchiolitis.
Acute asthma
The use of montelukast in acute asthma has received
very poor attention. High concentrations of CysLTs have
been found in urine patients with acute asthma exacer-
bations [52], and LTRAs administration could thus im-
prove symptoms control during asthma attacks.
There are no studies on oral montelukast use in chil-
dren under 1 year of life with acute wheezing. A RCT of
51 children aged 2 to 5 years with mild to moderate
asthma evaluated the use of montelukast combined with
albuterol at the first symptoms of an acute exacerbation
[52]. When compared to patients treated with albuterolalone, subjects who received montelukast showed lower
severity of symptoms 90 minutes after the onset of the
exacerbation. This difference lasted up to four hours
after the first symptoms, and a lower need for oral ster-
oids was also reported. Treatment with montelukast
initiated in children with intermittent asthma at the
onset of upper respiratory infections (URI) or acute
asthma, reduced symptoms (p = 0.049) and days off from
school (p < 0.0001), but did not affect the use of asthma
medications (p = 0.25) [33]. An additional RCT demon-
strated that in moderate-to-severe intermittent wheezing
a 7-days course of montelukast does not decrease oral
corticosteroid use over a 12-month period, when com-
pared with placebo or budesonide inhalation in addition
to albuterol (p = 0.15) [40]. Despite the association be-
tween URI and onset of asthma has been repeatedly
documented [1,33,36,37], a recent RCT of 300 preschool
children with URI showed that a 12-week treatment with
montelukast did not reduce the incidence of URI [53].
Given the controversial data available until now, we
believe that further studies are urgently needed to sup-
port the treatment with LTRAs of preschool children
with acute wheezing, especially in infants younger than
one year.
Main results from all the studies conducted in children
with preschool wheezing disorders treated with monte-
lukast, alone or combined with ICS, are summarized in
Table 1 and Table 2.
Adverse events
LTRAs are generally well tolerated. Most of the adverse
events described are mild (headache, gastrointestinal dis-
orders, pharyngitis, cutaneous rash and reversible altera-
tions in levels of serum transaminase) and do not
significantly differ from those described in subjects re-
ceiving placebo [54].
Among respiratory medications used in the Italian
pediatric population, montelukast is seldom prescribed
as off-label drug, and its use is overall increasing [55].
This trend reflects recommendations from asthma
guidelines, that support beneficial effects of LTRAs also
in children aged less than 6 years [29]. A recent review
on safety and tolerability of montelukast in children with
both episodic (viral) and persistent multi-trigger wheeze
concluded that its safety profile is comparable to that of
placebo [54]. Adverse events most frequently reported
include upper respiratory tract infections, worsening of
wheeze, fever and self-limited cough, particularly in pre-
school children.
Risk for hepatic toxicity appears lower for montelukast
than other molecules of the same group, and no
increased risk of hypertransaminasemia during the treat-
ment has been reported [45]. A large study on 1.948.297
children aged less than 5 years reported 3698 cases of
Table 1 Studies of preschool wheezing children treated with montelukast alone or with inhaled corticosteroids (ICS)
Author Pros Cons
Bisgaard [30] Protection against cold air-induced reactivity
Hakim [22] Reduced methacoline-induced reactivity
Wheezing (short-term Straub [31] Reduced airway resistance and exhaled nitric oxide
montelukast monotherapy) Straub [32] Improved lung function and symptom score
Robertson [33] Reduced healthcare resource use, symptoms,
time-off school/parent work
No effect on hospitalization rate,
symptoms duration, β2 or steroids use
Szefler [38] No difference versus budesonide for Higher rates of exacerbations
- time to 1st additional asthma drug at 12 weeks
- time to 1st attack requiring oral steroid
Wheezing (long-term Kooi [39] Montelukast versus fluticasone or placebo
montelukast In all groups In all groups: no differences
monotherapy) - Improved symptoms score in lung function
- Reduced blood eosinophils
Allen-Ramey [41] Emergency visits fewer versus fluticasone No differences in hospitalizations or
rescue drugs
Davies [35] Similar rates of healthcare resource of
cromolyn or ICS
Bisgaard [36] Lower
- rate of asthma exacerbations
- median time to first exacerbation
- rate of ICS courses
Bacharier [40] No difference in symptom free-days,
oral steroid, healthcare resource use
Wheezing Johnston Reduced risk of :
(montelukast + ICS) [44] - worsened asthma symptoms
- unscheduled physician visits
References are in parenthesis.
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risk of relevant adverse events is associated to ingestion
of more than 536 mg or 34 mg/kg [56]. No toxic effects
have been described in two asthmatic children aged 2
and 5 years who were managed at home and in an emer-
gency department, respectively, after unintentional poi-
soning [57]. This report concludes that montelukast
does not entail toxic effects for doses below 4.5 mg/kg.
Churg-Strauss syndrome (CSS) is a rare but life-
threatening granulomatous and eosinophilic vasculitis
that occurs preferentially in school-age, adolescents and
adults with pre-existing asthma [58]. Since the introduc-
tion of LTRAs, several studies reported the development
of this condition after the onset of the treatment, par-
ticularly with zafirlukast [59], but CSS has never been
described in preschool children.
The neuropsychiatric manifestations reported in old
children during montelukast treatment have never been
observed in preschool age. Nevertheless, even in adults
and adolescents, the results of the clinical trials do not
provide substantial evidence to support a causalassociation between montelukast therapy and such dis-
orders [60].
All the above reported data support a good safety pro-
file of montelukast and encourage its use in the clinical
practice. Future long-term studies in preschool children
will provide further information regarding potential ad-
verse events of LTRAs use in this age range.From asthma guidelines to recommendations
The main guidelines on asthma management (Global
Initiative for Asthma, GINA; British Thoracic Society,
BTS; National Institute of Health, NIH) have confirmed
the clinical utility of LTRAs in children older than five
years [15-17]. In school age children and adolescents,
LTRAs are recommended in mild persistent asthma as
second-line therapy in alternative to ICS, or in moderate
persistent asthma as add-on to ICS, in alternative to ICS
alone [17] with beneficial effects on asthma control and
on the number of exacerbations [16,61]. Moreover, regu-
lar treatment with LTRAs effectively protects against
Table 2 Studies of children with bronchiolitis and post-bronchiolitis, and acute asthma treated with montelukast
Author Pros Cons
No difference:
- in length of stay
Amirav [47] - in clinical severity score
- in cytokine levels in nasal lavage fluid





Proesmans [49] - of symptoms and disease-free
days and nights
- of n° of exacerbations
- of n° of unscheduled visits and
need of inhaled steroids
Higher percentage of symptom-free
days and nights
Bisgaard [50] Reduced daytime cough
Decreased exacerbations versus placebo
Kim [51] Reduced serum eosinophil-derived
neurotoxin levels compared with initial levels
Decreased cumulative recurrent wheezing
episodes at 12 months versus placebo
Harmanci [52] Reduced oral steroids need
Acute asthma Decreased lung index scores
and respiratory rate versus placebo
Hospitalization rates not significantly different
Robertson [33] Reduced healthcare resource use,
symptoms, time-off school/parent work
No effect on hospitalization rate,
symptoms duration, β2 or steroids use
Bacharier [40] No difference in symptom free-days, oral steroid,
healthcare resource use
References are in parenthesis.
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to the bronchoprotective effect [23].
In children younger than 5 years of age, only very few
RCTs have been conducted, and therefore the recom-
mendations made by official guidelines on LTRAs treat-
ment mainly derive from studies conducted in older
children. In the GINA guideline LTRAs are suggested
especially because of their efficacy in reducing virus-
induced exacerbations, which are extremely frequent at
preschool age [15]. According to the BTS document,
LTRAs may be administered in alternative to ICS, or as
an add-on therapy in children who do not fully respond
to ICS [16]. Finally, the NIH guideline recommends
LTRAs to young children to overcome the difficulties
due to the use of inhalator devices, or when compliance
is poor [17].
In 2008 two relevant documents have provided indi-
cations for asthma management in preschool age
[13,62]. First, the PRACTALL (“PRACTicing ALLergol-
ogy”) consensus report concluded that LTRAs are ef-
fective as short- or long-term therapy for controllingvirus-induced asthma exacerbations in children under
2 years of age, and may be used alone in alternative to
ICS in children 3 to 5 years old with intermittent or
mild persistent asthma, [13]. Second, a Task Force
committed by the European Respiratory Society (ERS)
identified two different wheezing phenotypes: a) epi-
sodic (viral) wheezing, characterized by intermittent
wheeze and no symptoms between episodes; and b)
multiple-trigger wheeze, induced by several stimuli in-
cluding exercise and allergens, in children who wheeze
both during and outside discrete episodes [62]. Indeed,
this classification has raised several concerns. The iden-
tification of the wheezing phenotype is generally based
on symptoms reported by parents, and a wide overlap-
ping of clinical symptoms and signs between the two
categories may occur [63]. Moreover, preschool wheez-
ing phenotypes can change over time, entailing relevant
modifications in previously established treatment deci-
sions [64]. As far as LTRAs, the ERS document con-
cluded that a trial with montelukast may be considered
in both multi-trigger and viral wheeze, but that further
Table 3 Keypoints in the use of montelukast in preschool








Effectiveness of combined therapy
with inhaled steroids in wheezing children
Reduction of
airway inflammation
Effectiveness in severe post-RSV
bronchiolitis wheeze
Excellent safety profile Effectiveness in acute exacerbation
Good compliance due to
oral single administration
Selection criteria of subjects with
wheezing to treat with monotherapy or
combined therapyv with inhaled steroids
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tions [62].
Important keypoints about montelukast in preschool
wheezing are summarized in Table 3. They include both
evidences definitively supporting its use in the clinical
practice, and uncertainties that still limit its prescription.Conclusions
The optimal therapeutic strategy for wheezing disorders
in early life remains elusive. The pathophysiology is still
poorly understood, and likely includes factors other than
airway inflammation [65]. Future research in this area
should hopefully incorporate consideration in particular
of the heterogeneous nature of asthma in preschool
children.
Since current recommendations on the use of monte-
lukast, both alone or combined with ICS, derive from
evidences in older children, further research is urgently
needed to confirm the effectiveness of LTRAs in young
wheezing children. Based on the current body of evi-
dence, there is rationale for further investigation of these
management strategies, including direct comparisons be-
tween ICS and LTRAs, as well as the role of long-acting
beta-agonists, potentially targeting the subpopulations of
early wheezers who are at highest risk for the persistence
of asthma symptoms.
An additional important keypoint is represented by
the identification of subjects who wheeze and may bene-
fit from montelukast alone, or from combined therapy.
In particular, combined therapy with ICS plus LTRAs
might result effective in achieving symptom control and
in decreasing health care resource utilization [66]. The
intermittent use of montelukast for treating in particular
preschool children with severe recurrent wheeze should
be more investigated. Finally, further studies should be
promoted to confirm that montelukast is effective in
preschool acute asthma [53] and to clarify the controver-
sial data published on LTRAs effects in post-RSV bron-
chiolitis [37,48,49].Montelukast is a safe drug, with a prominent anti-
inflammatory activity to the airways [31], and also a
strong bronchoprotective effect [30]. Montelukast admi-
nistered as inhaled drug has been recently reported to
provide a significant bronchodilation compared to pla-
cebo, in adolescents and adults with chronic asthma
[67], but no studies are available in school-age or pre-
school children.
The excellent safety profile of montelukast, and the
possibility of oral administration, which entails better
compliance from young children, represent the main
strengths of its use in preschool children. Therefore,
montelukast represents a valid alternative to ICS in
poorly compliant children, or in subjects who show ad-
verse effects related to long-term steroid therapy.
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